RSV protection extended: Clesrovimab shows promise for kids' second season
A single higher dose of clesrovimab (Enflonsia) appears safe for high-risk children heading into their second RSV season, according to phase 3 SMART trial data. The long-acting monoclonal antibody was well-tolerated, with no treatment-related serious adverse events. The FDA has accepted Merck's application to expand clesrovimab's approval to children under age 2 at high risk for severe RSV disease, with a decision expected by March 2027.
ResMed's rough road ahead: FDA recall, rising costs, and stiff competition weigh on outlook
The CDC finally has a permanent director — meet Dr. Erica Schwartz
Federal government moves to shut down organ procurement organization over serious patient safety failures
FDA approves viral immunotherapy for treatment-resistant melanoma after two prior rejections
Jazz pulls the plug on lurbinectedin's second-line lung cancer label after trial failure
FDA approves Tudriqev + Opdivo combo for advanced melanoma after two prior rejections
FDA finally greenlights Replimune's melanoma drug after two rejections
FDA greenlights next-gen implant for urgency urinary incontinence with 15-year durability
FDA greenlights first-ever mRNA flu vaccine — and it's a big deal
Pfizer's Litfulo shows promising results for vitiligo in two major phase 3 trials
Explore all the latest healthcare news and insights